 Home > Active Ingredient News > Diagnostic Test > 110 pharmaceutical companies posted their first quarter transcripts!

110 pharmaceutical companies posted their first quarter transcripts!

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

drug test preparation

high pressure cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

With the intensive disclosure of the 2020 annual reports of listed companies, the first quarter report card of 2021 will follow.

A-share pharmaceutical companies' performance in the first quarter of 2021

A-share pharmaceutical company's first quarter 2021 performance report

A-share pharmaceutical companies' performance forecast for the first quarter of 2021

90% of the first quarter Announcement! 52 companies doubled, 18 companies turned losses, only 2 companies lost first

According to statistics, there are currently 110 pharmaceutical companies in A-shares that have disclosed their performance in the first quarter of 2021.

Brokerage analysis pointed out that the first quarter of last year was affected by the epidemic and the performance of many listed companies was impacted.

Qianhong Pharmaceutical's net profit in the first quarter of 2021 is expected to be 54.

Jinling Pharmaceuticals stated that the new crown epidemic broke out in early 2020, and the company's medical institutions invested various medical resources and medical staff to fight the new crown pneumonia epidemic.

Changchun Hi-tech, China Resources Sanjiu.

Net profit: 841 million to 895 million yuan

Year-on-year growth: 55%~65%

Regarding the substantial growth in performance in the first quarter, Changchun Hi-tech pointed out that it was mainly due to the income growth of the backbone pharmaceutical companies holding it.

Yiling Pharmaceutical

Net profit: 557 million to 701 million yuan

Year-on-year growth: 50%~60%

Yiling Pharmaceutical said that on the one hand, the company's winning the first prize of the National Science and Technology Progress Award has gradually shown its influence on the company's cardiovascular and cerebrovascular products market, and market demand has grown steadily.

China Resources Sanjiu

Net profit: 600 million to 710 million yuan

Year-on-year growth: 12.

Regarding the performance growth in the first quarter, China Resources Sanjiu stated that the company conformed to the development trend of the industry, continued to carry out innovation, transformation and upgrading, continuously optimized product structure, strengthened brand building, and promoted profitability.

Thermal Scene Biology

Net profit: 560 million to 660 million yuan

Year-on-year growth: 109126%~128630%

On April 13, Hotview Bio announced its first-quarter performance forecast, with an estimated net profit of 560 million to 660 million yuan, a year-on-year increase of more than 1,000 times, and it has become the "pre-increasing king" of performance.

Source: Oriental Fortune.

Statistics are as of the close on the morning of April 16.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.